SEARCH

Search Details

KITAI HIDENORI

Faculty of Medicine　Internal Medicine　Internal MedicineAssistant Professor
Hokkaido University HospitalAssistant Professor

Researcher basic information

■ Degree
  • Doctor of Philosophy, Hokkaido University, Dec. 2017
■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
  • 30975412
ORCID IDJ-Global ID■ Research Keywords and Fields
Research Keyword
  • KRAS
  • 分子標的治療
  • Lung cancer
Research Field
  • Life Science, Respiratory medicine
  • Life Science, Tumor diagnostics and therapeutics
■ Educational Organization

Career

■ Career
Career
  • Oct. 2022 - Present
    北海道大学大学院医学研究院, 呼吸器内科学教室, 助教, Japan
  • Jan. 2019 - Oct. 2022
    Memorial Sloan Kettering Cancer Center, Postdoctoral researcher, United States
  • Apr. 2017 - Dec. 2018
    北海道大学病院呼吸器内科, 医員
  • Apr. 2014 - Mar. 2017
    金沢大学がん進展制御研究所, 特別研究生, Japan
  • Apr. 2012 - Mar. 2014
    北海道大学病院, 内科Ｉ, 医員
  • Apr. 2011 - Mar. 2012
    国立病院機構北海道がんセンター, 呼吸器内科
  • Apr. 2010 - Mar. 2011
    KKR札幌医療センター, 呼吸器内科
  • Apr. 2009 - Mar. 2010
    帯広厚生病院, 初期研修医
  • Apr. 2008 - Mar. 2009
    北海道大学病院, 初期研修医
Educational Background
  • Apr. 2013 - Dec. 2017, Hokkaido University, Graduate School of Medicine, 呼吸器内科学講座, Japan
  • Apr. 2002 - Mar. 2008, Hokkaido University, School of Medicine, 医学科, Japan

Research activity information

■ Awards
  • 2018, 上原記念財団海外留学助成リサーチフェローシップ
  • 2017, 北海道大学大学院医学研究科・医学部医学科 優秀論文賞
■ Papers
  • Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report.
    Murayama C; Ikezawa Y; Shiiya C; Oda Y; Ikezawa M; Matsunaga A; Tsuji K; Shoji T; Furuta M; Takashima Y; Kitai H; Sakakibara-Konishi J; Konno S
    Respiratory medicine case reports, 21 Apr. 2026
    Scientific journal, Immune checkpoint inhibitors, such as atezolizumab, have become integral to the treatment of various malignancies and have significantly improved clinical outcomes by enhancing host antitumor immune responses. However, with their expanding clinical use, immune-related adverse events (irAEs) have been increasingly recognized. These events may involve any organ system and pose new challenges in patient management. Most irAEs occur within the first few months following treatment initiation; however, they may also develop unexpectedly after prolonged periods of stable therapy. Late-onset irAEs are generally mild to moderate in severity, although a subset can progress to severe forms. Dermatological toxicities are the most frequently observed irAEs. Although most cutaneous reactions are mild and manageable, severe skin toxicities, although relatively uncommon, can substantially impair patients' quality of life and may necessitate treatment modification or discontinuation. Psoriasis is a recognized cutaneous irAE that may present either as a de novo disease in patients without a history of psoriasis or as an exacerbation of pre-existing psoriasis. This case report describes a rare presentation of severe psoriasis that developed following long-term atezolizumab therapy and improved following treatment with oral prednisolone in 61-year-old man with pulmonary large-cell neuroendocrine carcinoma.
  • Amivantamab-Associated Vasculitis in a Patient With EGFR Exon 20 Insertion Non–Small Cell Lung Cancer: A Case Report
    Daisuke Morinaga; Megumi Furuta; Doppo Fukui; Yuki Matsuura; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Hidenori Kitai; Zenichi Tanei; Jun Sakakibara-Konishi; Satoshi Konno
    Clinical Lung Cancer, Mar. 2026
    English, Scientific journal
  • Limited-Stage Small-Cell Lung Cancer With Severe Paraneoplastic Limbic Encephalitis Successfully Treated With Chemoradiotherapy Followed by Immune Checkpoint Inhibitor Maintenance Therapy: A Case Report
    Daisuke Morinaga; Hidenori Kitai; Hanko Sato; Doppo Fukui; Wataru Harabayashi; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Megumi Furuta; Akihiko Kudo; Shintaro Fujii; Hisashi Uwatoko; Hiroaki Yaguchi; Keiko Tanaka; Ichiro Yabe; Jun Sakakibara-Konishi; Satoshi Konno
    Clinical Lung Cancer, Mar. 2026
    Scientific journal
  • Successful treatment of huntingtin-interacting protein-1-anaplastic lymphoma kinase-positive lung cancer with severe airway stenosis using silicone stent placement and alectinib.
    Sato Y; Kitai H; Takashima Y; Shinagawa N; Sakakibara-Konishi J; Ohkawa H; Hatanaka KC; Hatanaka Y; Yokouchi H; Konno S
    Respiratory investigation, 11 Nov. 2025
    Scientific journal, Huntingtin-interacting protein 1 (HIP1)-anaplastic lymphoma kinase (ALK) is a relatively rare fusion in ALK-positive lung cancers. HIP1-ALK (H19:A20) is a rare variant among HIP1-ALK-positive lung cancers, and data on the efficacy of ALK tyrosine kinase inhibitors are limited. We report a 37-year-old man with HIP1-ALK (H19:A20) lung adenocarcinoma treated with silicone stent placement and alectinib. Stent placement was effective in improving symptoms, and the best treatment response with alectinib was a partial response. Routine ALK screening using IHC or comprehensive genomic profiling should be considered for patients with lung cancer with suspected ALK gene.
  • Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
    Sawana Ono; Hirokazu Taniguchi; Koji Kuroda; Teppei Hashimoto; Asuka Okada; Yasuhiro Goto; Hidenori Kitai; Yoichi Nakamura; Shinsuke Ogusu; Tetsunari Hase; Takayo Ota; Noriyuki Ebi; Makoto Furugen; Taishi Harada; Yoshiaki Kinoshita; Takaki Mizoguchi; Katsumi Nakatomi; Yoshifumi Soejima; Takahiro Yamada; Shinnosuke Takemoto; Hiroshi Mukae
    Lung Cancer, Sep. 2025
    Scientific journal
  • Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
    Daisuke Morinaga; Jun Sakakibara-Konishi; Kamada R; Kashima M; Tsuji K; Ito S; Furuta M; Shoji T; Takashima Y; Kitai H; Ikezawa Y; Taguchi H; Kato T; Shinomiya Y; C Hatanaka K; Hatanaka Y; Konno S
    Thoracic cancer, 01 Jul. 2025
    Scientific journal,

    Background

    During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP.

    Methods

    A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy.

    Results

    Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights.

    Conclusions

    Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
  • Midkine Promotes Tumor Growth and Attenuates the Effect of Cisplatin in Small Cell Lung Cancer.
    Ito S; Jun Sakakibara-Konishi; Sato M; Shoji T; Furuta M; Takahashi H; Tsuji K; Daisuke Morinaga; Kashima M; Kitai H; Kikuchi J; Kikuchi E; Hatanaka KC; Hatanaka Y; Kyoko Hida; Noguchi T; Konno S
    Cancer medicine, 01 Jul. 2025
    Scientific journal,

    Purpose

    Small cell lung cancer (SCLC) is a highly aggressive disease associated with poor patient survival rates. The addition of an anti-programmed death ligand 1 antibody to platinum combination chemotherapy can improve its prognosis. However, only a few patients achieve a long-term response; thus, establishing new therapies for SCLC is crucial. Midkine (MDK) is a heparin-binding growth factor involved in various biological processes, including cell proliferation and chemotherapeutic resistance, in diverse cancers. MDK has garnered attention as a therapeutic and diagnostic target for several cancers; however, only a few studies have evaluated its expression and function in SCLC. This study aimed to evaluate the MDK expression in human SCLC tissue and human SCLC cell lines, and to clarify its function in tumorigenesis.

    Methods

    MDK expression was analyzed in vitro and in vivo through ELISA, immunohistochemistry, and western blotting. Its effects on cell proliferation, as well as the effects of cisplatin, were evaluated using the MTT assay.

    Results

    MDK was pathologically expressed in human SCLC tumor tissues but not in normal lung tissues. Serum MDK concentrations in patients with SCLC reflected the SCLC tumor burden and were correlated with response to treatment. Moreover, MDK induced cell proliferation and attenuated the effects of cisplatin in SCLC cell lines. An MDK inhibitor and cisplatin exerted synergistic antitumor effects both in vitro and in vivo. Furthermore, MDK positively regulated the AKT pathway.

    Conclusion

    Our findings indicate that MDK promotes cell proliferation and chemotherapeutic resistance by activating the AKT pathway in SCLC cells. Therefore, MDK may be a potential therapeutic and diagnostic target for SCLC.
  • 低用量のセルペルカチニブが奏効したRET融合遺伝子陽性非小細胞肺癌の1例
    島田 琉海; 庄司 哲明; 高橋 宏典; 猪狩 智生; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲; 伊藤 健一郎; 福土 将秀
    肺癌, 65, 3, 205, 205, (NPO)日本肺癌学会, Jun. 2025
    Japanese
  • 術前化学免疫療法1コースで免疫関連有害事象により外科切除に移行し病理学的奏効を得た肺扁平上皮癌の1例
    鎌田 凌平; 庄司 哲明; 池澤 靖元; 久世 瑞穂; 東 陸; 松永 章宏; 畠山 酉季; 辻 康介; 高橋 宏典; 高島 雄太; 古田 恵; 北井 秀典; 榊原 純; 今野 哲; 宮石 陸; 大塚 紀幸; 田中 伸哉; 加藤 達哉
    肺癌, 65, 3, 207, 207, (NPO)日本肺癌学会, Jun. 2025
    Japanese
  • Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy
    Daisuke Morinaga; Jun Sakakibara-Konishi; Yasutaka Kawai; Yumi Morinaga; Shohei Mizobuchi; Yoshihiro Okamoto; Yasunari Yamanaka; Kei Takahashi; Hajime Kikuchi; Noriaki Sukoh; Taichi Takashina; Hidenori Kitai; Satoshi Konno
    Respiratory Investigation, May 2025
    English, Scientific journal
  • 経過中に腹膜播種による腹水が乳び化を呈した,胸腺腫の1例
    武藤 ほの; 庄司 哲明; 古川 貴啓; 辻 康介; 佐藤 峰嘉; 高島 雄太; 古田 恵; 北井 秀典; 池澤 靖元; 木野田 直也; 阿保 大介; 榊原 純; 今野 哲
    日本呼吸器学会誌, 14, 増刊, 366, 366, (一社)日本呼吸器学会, Mar. 2025
    Japanese
  • Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report.
    Hatakeyama Y; Sakakibara-Konishi J; Tarumi M; Tsuji K; Takahashi H; Furuta M; Takashima Y; Kitai H; Shoji T; Ikezawa Y; Konno S
    Respiratory medicine case reports, 15 Feb. 2025
    Scientific journal, Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD. In August 2016, the patient developed ILD with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM). She received triple therapy comprising prednisolone, tacrolimus and azathioprine. In October 2021, the patient complained of lateral chest pain and back pain. In January 2022, computed tomography (CT) revealed an anterior mediastinal tumor, and percutaneous biopsy resulted in a diagnosis of thymic carcinoma with Masaoka classification IVb. In March 2022, first-line treatment with four cycles of carboplatin (area under the curve, 6) + paclitaxel (200 mg/m2) was initiated. Although a partial response was achieved, in September 2022, CT demonstrated progressive disease (PD). Therefore, in October 2022, Lenvatinib (24 mg) was started as the second-line treatment. The best response was stable disease; moreover, although lenvatinib dose reduction was required owing to adverse events, such as biliary-tract infection and stomatitis. The patient did not experience ILD exacerbation. Lenvatinib (14 mg) was continued until PD was observed in March 2023. Our findings suggest that lenvatinib is a viable treatment option for thymic carcinoma with ILD.
  • 気管支狭窄拡張術後にALK-TKIを導入したHIP1-ALK陽性肺癌の1例
    佐藤 祐麻; 北井 秀典; 田上 敬太; 石田 有莉子; 篠崎 鮎香; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 庄司 哲明; 池澤 靖元; 榊原 純; 品川 尚文; 今野 哲; 大川 紘弥; 大塚 紀幸; 畑中 佳奈子; 畑中 豊; 横内 浩
    肺癌, 65, 1, 65, 65, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • 全身療法中にoligoprogression/oligorecurrenceを認めた非小細胞肺癌症例の検討
    鎌田 凌平; 森永 大亮; 榊原 純; 古川 貴啓; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 庄司 哲明; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 田口 大志; 加藤 達哉
    肺癌, 65, 1, 66, 67, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • 小細胞肺癌との鑑別に苦慮した胸部SMARCA4欠損未分化腫瘍の1例
    溝渕 匠平; 榊原 純; 棟方 奈菜; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 今野 哲; 加藤 憲士郎; 大塚 紀幸; 種井 善一; 田中 伸哉
    肺癌, 65, 1, 67, 67, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • EGFR遺伝子変異陽性進行再発非小細胞肺癌における免疫チェックポイント阻害剤の治療についての後方視的検討
    古川 貴啓; 庄司 哲明; 酒井 碧; 佐々木 賢太; 畠山 酉季; 辻 康介; 佐藤 峰嘉; 高橋 宏典; 古田 恵; 高島 雄太; 北井 秀典; 池澤 靖元; 榊原 純; 今野 哲
    肺癌, 65, 1, 68, 68, (NPO)日本肺癌学会, Feb. 2025
    Japanese
  • Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
    Jun Sakakibara-Konishi; Hirofumi Takahashi; Kenichiro Ito; Tomoo Ikari; Yasuyuki Ikezawa; Hidenori Kitai; Megumi Furuta; Yuta Takashima; Tetsuaki Shoji; Masahide Fukudo; Satoshi Konno
    Respiratory Medicine Case Reports, 53, 102176, 102176, Elsevier BV, 2025
    Scientific journal
  • WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
    Yamamoto G; Tanaka K; Kamata R; Saito H; Yamamori-Morita T; Nakao T; Liu J; Mori S; Yagishita S; Hamada A; Shinno Y; Yoshida T; Horinouchi H; Ohe Y; Watanabe SI; Yatabe Y; Kitai H; Konno S; Kobayashi SS; Ohashi A
    Cancer letters, 24 Dec. 2024
    Scientific journal, KRASG12C inhibitors sotorasib and adagrasib have been approved for the treatment of KRASG12C-mutant non-small cell lung cancer (NSCLC). However, the efficacy of single-agent treatments is limited, presumably due to multiple resistance mechanisms. To overcome these therapeutic limitations, combination strategies that potentiate the antitumor efficacy of KRASG12C inhibitors must be developed. Through unbiased high-throughput screening of 1395 kinase inhibitors, we identified adavosertib, a WEE1 inhibitor, as a promising combination partner of sotorasib. The combination of sotorasib and adavosertib exhibited synergistic antiproliferative activities both in vitro and in vivo, irrespective of TP53, STK11, and KEAP1 co-mutation profiles. WEE1 inhibition potentiated MCL-1-mediated apoptosis in sotorasib-treated cancer cells. Mechanistically, the combination downregulated MCL-1 protein levels by attenuating de novo translation and enhancing its degradation. WEE1 overexpression conferred resistance against sotorasib via MCL-1 upregulation. Moreover, cells that acquired sotorasib resistance profoundly upregulated both WEE1 and MCL-1 proteins, highlighting WEE1 as a crucial driver of sotorasib resistance. Importantly, WEE1 inhibition re-sensitized resistant cells to sotorasib treatment. The current findings demonstrate that combined inhibition of KRASG12C and WEE1 not only exhibits synergistic antitumor efficacy but also overcomes resistance to KRASG12C inhibitors, thus representing a novel therapeutic strategy for KRASG12C-mutant NSCLC.
  • Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
    Hidenori Kitai; Philip H. Choi; Yu C. Yang; Jacob A. Boyer; Adele Whaley; Priya Pancholi; Claire Thant; Jason Reiter; Kevin Chen; Vladimir Markov; Hirokazu Taniguchi; Rui Yamaguchi; Hiromichi Ebi; James Evans; Jingjing Jiang; Bianca Lee; David Wildes; Elisa de Stanchina; Jacqueline A. M. Smith; Mallika Singh; Neal Rosen
    Nature Communications, 15, 1, Springer Science and Business Media LLC, 19 Jul. 2024
    Scientific journal, Abstract

    Current KRASG12C (OFF) inhibitors that target inactive GDP-bound KRASG12C cause responses in less than half of patients and these responses are not durable. A class of RASG12C (ON) inhibitors that targets active GTP-bound KRASG12C blocks ERK signaling more potently than the inactive-state inhibitors. Sensitivity to either class of agents is strongly correlated with inhibition of mTORC1 activity. We have previously shown that PI3K/mTOR and ERK-signaling pathways converge on key cellular processes and that inhibition of both pathways is required for inhibition of these processes and for significant antitumor activity. We find here that the combination of a KRASG12C inhibitor with a selective mTORC1 kinase inhibitor causes synergistic inhibition of Cyclin D1 expression and cap-dependent translation. Moreover, BIM upregulation by KRASG12C inhibition and inhibition of MCL-1 expression by the mTORC1 inhibitor are both required to induce significant cell death. In vivo, this combination causes deep, durable tumor regressions and is well tolerated. This study suggests that the ERK and PI3K/mTOR pathways each mitigate the effects of inhibition of the other and that combinatorial inhibition is a potential strategy for treating KRASG12C-dependent lung cancer.
  • Oncogene alterations in non-small cell lung cancer with FGFR1 amplification-novel approach to stratify patients who benefit from FGFR inhibitors.
    Kitai H; Hiromichi Ebi
    Translational lung cancer research, 08 Mar. 2024
    Scientific journal
  • Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer.
    Kosuke Tsuji; Eiki Kikuchi; Yuta Takashima; Tetsuaki Shoji; Hirofumi Takahashi; Shotaro Ito; Daisuke Morinaga; Masahiro Kashima; Makie Maeda; Hidenori Kitai; Junko Kikuchi; Jun Sakakibara-Konishi; Satoshi Konno
    Cell cycle (Georgetown, Tex.), 1, 11, 17 Aug. 2023, [International Magazine]
    English, Scientific journal, Mitotic slippage, which enables cancer cells to bypass cell death by transitioning from mitosis to the G1 phase without undergoing normal cytokinesis, is one likely mechanism of paclitaxel (PTX) resistance. DNA double-strand breaks (DSBs) in the G1 phase are mainly repaired through non-homologous end joining (NHEJ). Therefore, inhibiting NHEJ could augment the PTX-induced cytotoxicity by impeding the repair of PTX-induced DSBs during the G1 phase following mitotic slippage. We aimed to evaluate the effects of NHEJ inhibition on mitotic slippage after PTX treatment in non-small cell lung cancer (NSCLC). H1299, A549, H1975, and H520 NSCLC cell lines were employed. In addition, A-196 and JQ1 were used as NHEJ inhibitors. H1299 cells were PTX-resistant and exhibited an increased frequency of mitotic slippage upon PTX treatment. NHEJ inhibitors significantly augmented the PTX-induced cytotoxicity, DSBs, and apoptosis in H1299 cells. The newly generated PTX-resistant cells were even more prone to mitotic slippage following PTX treatment and susceptible to the combined therapy. Docetaxel further demonstrated synergistic effects with the NHEJ inhibitor in PTX-resistant cells. NHEJ inhibition may overcome intrinsic or acquired PTX resistance resulting from mitotic slippage by synergistically increasing the cytotoxic effects of antimitotic drugs in NSCLC.
  • 80歳以上の高齢者に対する経気管支生検の安全性と有用性の検討
    畠山 酉季; 高島 雄太; 鈴木 孝敏; 棟方 奈菜; 中村 友彦; 高橋 宏典; 古田 恵; 北井 秀典; 庄司 哲明; 朝比奈 肇; 菊地 英毅; 菊地 順子; 榊原 純; 品川 尚文; 今野 哲
    気管支学, 45, Suppl., S217, S217, (一社)日本呼吸器内視鏡学会, Jun. 2023
    Japanese
  • WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
    Hirokazu Taniguchi; Rebecca Caeser; Shweta S. Chavan; Yingqian A. Zhan; Andrew Chow; Parvathy Manoj; Fathema Uddin; Hidenori Kitai; Rui Qu; Omar Hayatt; Nisargbhai S. Shah; Álvaro Quintanal Villalonga; Viola Allaj; Evelyn M. Nguyen; Joseph Chan; Adam O. Michel; Hiroshi Mukae; Elisa de Stanchina; Charles M. Rudin; Triparna Sen
    Cell Reports, May 2022
    Scientific journal
  • 気管支鏡検査におけるFFPE組織検体および細胞検体を用いたROS1融合遺伝子の検査成功率の検証
    辻 康介; 榊原 純; 北井 秀典; 猪狩 智生; 佐藤 峰嘉; 高橋 宏典; 國崎 守; 庄司 哲明; 高島 雄太; 古田 恵; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 樋田 泰浩; 加賀 基知三; 大井 優子; 中條 聖子; 畑中 佳奈子; 畑中 豊; 松野 吉宏; 今野 哲
    気管支学, 41, 6, 678, 678, (NPO)日本呼吸器内視鏡学会, Nov. 2019
    Japanese
  • Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer
    Jun Sakakibara-Konishi; Hidenori Kitai; Yasuyuki Ikezawa; Yutaka Hatanaka; Takaaki Sasaki; Ryohei Yoshida; Shinichi Chiba; Shingo Matsumoto; Koichi Goto; Hidenori Mizugaki; Naofumi Shinagawa
    Clinical Lung Cancer, 20, 5, e555, e559, Elsevier BV, Sep. 2019
    Scientific journal
  • Response to First-Line Osimertinib Treatment in Non–Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations
    Tomoo Ikari; Jun Sakakibara-Konishi; Gaku Yamamoto; Hidenori Kitai; Hidenori Mizugaki; Hajime Asahina; Eiki Kikuchi; Naofumi Shinagawa
    Clinical Lung Cancer, 20, 4, e531, e533, Elsevier BV, Jul. 2019
    Scientific journal
  • Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment
    Gaku Yamamoto; Jun Sakakibara-Konishi; Tomoo Ikari; Hidenori Kitai; Hidenori Mizugaki; Hajime Asahina; Eiki Kikuchi; Naofumi Shinagawa
    Journal of Thoracic Oncology, 14, 5, e97, e99, Elsevier BV, May 2019
    Scientific journal
  • Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
    Hiroshi Kotani; Yuta Adachi; Hidenori Kitai; Shuta Tomida; Hideaki Bando; Anthony C. Faber; Takayuki Yoshino; Dominic C. Voon; Seiji Yano; Hiromichi Ebi
    Oncogene, 37, 13, 1775, 1787, Springer Science and Business Media LLC, 19 Jan. 2018
    Scientific journal
  • A clinical analysis of 10 cases with oligometastases of non-small cell carcinoma
    Kunisaki, M.; Sakakibara, J.; Kikuchi, H.; Kitai, H.; Mizugaki, H.; Asahina, H.; Kikuchi, E.; Shinagawa, N.; Nishimura, M.
    Japanese Journal of Lung Cancer, 58, 7, 2018
    Scientific journal
  • Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
    Kyung-A Song; Matthew J. Niederst; Timothy L. Lochmann; Aaron N. Hata; Hidenori Kitai; Jungoh Ham; Konstantinos V. Floros; Mark A. Hicks; Haichuan Hu; Hillary E. Mulvey; Yotam Drier; Daniel A.R. Heisey; Mark T. Hughes; Neha U. Patel; Elizabeth L. Lockerman; Angel Garcia; Shawn Gillepsie; Hannah L. Archibald; Maria Gomez-Caraballo; Tara J. Nulton; Brad E. Windle; Zofia Piotrowska; Sinem E. Sahingur; Shirley M. Taylor; Mikhail Dozmorov; Lecia V. Sequist; Bradley Bernstein; Hiromichi Ebi; Jeffrey A. Engelman; Anthony C. Faber
    Clinical Cancer Research, 24, 1, 197, 208, American Association for Cancer Research (AACR), 01 Jan. 2018
    Scientific journal
  • Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer
    Yuta Adachi; Kazuyoshi Watanabe; Kenji Kita; Hidenori Kitai; Hiroshi Kotani; Yuki Sato; Naohiko Inase; Seiji Yano; Hiromichi Ebi
    Carcinogenesis, 38, 11, 1063, 1072, Oxford University Press (OUP), 31 Aug. 2017
    Scientific journal
  • Improvements of visual function and outer retinal morphology following spontaneous regression of cancer in anti-recoverin cancer-associated retinopathy
    Suimon, Y.; Saito, W.; Hirooka, K.; Kanda, A.; Kitai, H.; Sakakibara-Konishi, J.; Ishida, S.
    American Journal of Ophthalmology Case Reports, 5, 137, 140, 2017, [International Magazine]
    English, Scientific journal
  • Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
    Kitai, H.; Ebi, H.
    Small GTPases, 8, 3, 2017
    Scientific journal
  • Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
    Hidenori Kitai; Hiromichi Ebi; Shuta Tomida; Konstantinos V. Floros; Hiroshi Kotani; Yuta Adachi; Satoshi Oizumi; Masaharu Nishimura; Anthony C. Faber; Seiji Yano
    Cancer Discovery, 6, 7, 754, 769, American Association for Cancer Research (AACR), 30 Jun. 2016
    Scientific journal
  • Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration.
    Azusa Tanimoto; Takeuchi S; Hiroshi Yaegashi; Kotani H; Kitai H; Nanjo S; Hiromichi Ebi; Yamashita K; Mouri H; Ohtsubo K; Ikeda H; Yano S
    Molecular and clinical oncology, 25 Jan. 2016
    Scientific journal, A 76-year-old female in whom a renal cell carcinoma (RCC) lesion was resected 19 years previously presented to our hospital with cognitive dysfunction. Magnetic resonance imaging and computed tomography revealed nodules in the brain, lung, adrenal gland and a pelvic osteolytic lesion. To identify the primary cancer site, the present study performed endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the left adrenal lesion. Consequently, the pathological findings of the tissue obtained by EUS-FNA were similar to those of the previous nephrectomy specimen, revealing that the adrenal lesion was the recurrence of RCC. The majority of the metastatic lesions in the patient were reduced in size by the multiple kinase inhibitor, pazopanib. Contralateral adrenal metastasis of RCC is rare and the use of EUS-FNA in the diagnosis of adrenal lesions remains to be elucidated. This is a rare case of adrenal lesion, diagnosed by EUS-FNA. Therefore, EUS-FNA is considered to be a useful diagnostic modality of adrenal metastases from unidentified primary tumor types.
  • Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
    H Kotani; H Ebi; H Kitai; S Nanjo; K Kita; T G Huynh; A Ooi; A C Faber; M Mino-Kenudson; S Yano
    Oncogene, 35, 27, 3587, 3597, Springer Science and Business Media LLC, 09 Nov. 2015
    Scientific journal
  • BIM遺伝子多型を有するEGFR遺伝子変異肺癌に対する次世代EGFR阻害薬の効果とHDAC阻害薬併用の有用性
    谷本 梓; 竹内 伸司; 北井 秀典; 南條 成輝; 衣斐 寛倫; 矢野 聖二
    日本呼吸器学会誌, 4, 増刊, 170, 170, (一社)日本呼吸器学会, Mar. 2015
    Japanese
  • 当院における外来化学療法の現況
    毛利 久継; 谷本 梓; 北井 秀典; 小谷 浩; 南條 成輝; 竹内 伸司; 衣斐 寛倫; 大坪 公士郎; 矢野 聖二
    日本内科学会雑誌, 104, Suppl., 190, 190, (一社)日本内科学会, Feb. 2015
    Japanese
  • 当院の外来化学療法室における過敏症とinfusion reactionの発現頻度と実態
    北井 秀典; 谷本 梓; 小谷 浩; 南條 成輝; 竹内 伸司; 衣斐 寛倫; 毛利 久継; 大坪 公士郎; 矢野 聖二
    日本内科学会雑誌, 104, Suppl., 240, 240, (一社)日本内科学会, Feb. 2015
    Japanese
  • Spontaneous regression of small cell lung cancer combined with cancer associated retinopathy
    Hidenori Kitai; Jun Sakakibara-Konishi; Satoshi Oizumi; Yoshihiko Hirohashi; Wataru Saito; Atsuhiro Kanda; Noriyuki Sato; Masaharu Nishimura
    LUNG CANCER, 87, 1, 73, 76, Jan. 2015, [Peer-reviewed], [International Magazine]
    English, Scientific journal
  • 当院における悪性胸膜中皮腫27例の検討
    菊池 創; 朝比奈 肇; 北井 秀典; 池澤 靖元; 高階 太一; 品川 尚文; 榊原 純; 大泉 聡史; 西村 正治; 樋田 泰浩; 加賀 基知三; 井上 哲也; 加藤 徳雄
    肺癌, 53, 7, 918, 918, (NPO)日本肺癌学会, Dec. 2013, [Peer-reviewed]
    Japanese
■ Other Activities and Achievements
■ Books and other publications
  • KRAS変異肺癌における分子標的治療
    Bio clinica 北隆館, Mar. 2026, [Single work]
■ Syllabus
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
■ Affiliated academic society
  • 日本癌学会
  • 日本臨床腫瘍学会
  • 呼吸器内視鏡学会
  • 日本呼吸器学会
  • 日本内科学会
  • 日本肺癌学会
■ Research Themes
  • ひと・AI/DX・しくみの三位一体的整備による次世代AI活用・データ駆動・情報循環型医学研究の戦略的推進
    革新的研究開発推進基金補助金
    Oct. 2025 - Mar. 2028
    国立研究開発法人日本医療研究開発機構, Principal investigator, 25147880
  • Uncovering the mechanisms of adaptive resistance to KRAS-specific inhibitor and development of novel therapeutic strategies in KRAS-mutant lung cancer
    Grants-in-Aid for Scientific Research
    01 Apr. 2024 - 31 Mar. 2027
    北井 秀典
    Japan Society for the Promotion of Science, Grant-in-Aid for Early-Career Scientists, Hokkaido University, 24K19078
  • KRAS変異肺癌におけるKRAS特異的阻害薬の耐性機序の解明と新規治療開発
    第40回寿原記念財団研究助成
    Apr. 2026 - Mar. 2027
    Principal investigator